TP53 and type 2 diabetes mellitus: In groups treated by Etomoxir, MitoQ and PFT-α, osteogenic differentiation was significantly improved, indicating that FAO, mitochodnrial ROS generation and P53 activation were involved in the reduction of osteogenic differentiation, which played a role, at least partly, in T2DM-associated bone loss.